The IPO train continues to barrel down the tracks as more life sciences companies announced and closed their initial public offerings, bringing millions more to their coffers.
Recent personnel movement throughout the healthcare industry includes a new CEO for both U.K.-based Orbit Discovery and Netherlands-based Azafaros.
The first half of 2021 saw a flurry of IPOs as multiple companies make the move to become publicly traded.
Innate Pharma has an alternative to T cell-based immunotherapy that has the potential to quickly and safely eradicate solid and metastatic tumors in the body.
PerkinElmer Inc. expanded the company’s presence in cell biology with the $260 million acquisition of Massachusetts-based Nexcelom Bioscience.
The world at large has become more familiar with mRNA technology due to vaccines developed against Covid-19. Now the world will be introduced to a new type of RNA-based medicine called Endless RNA, or eRNA for short.
Flagship Pioneering launched a new company called Inzen Therapeutics, which will discover and develop a new class of medicines based on a new area of biology that will provide new therapeutic approaches to multiple types of diseases.
AstraZeneca is acquiring Alexion Pharmaceuticals for $39 billion, with the deal expected to close in the third quarter of 2021.
AstraZeneca entered into a definitive agreement to acquire Alexion Pharmaceuticals for a total consideration to Alexion shareholders of $39 billion or $175 per share.
Blocking TNF production could offer a more effective solution for the treatment of COVID-19.